Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis (formerly Sanofi-Synthelabo) covers the period ending August 31, 2004. The report serves to incorporate by reference two press releases and a presentation delivered to financial analysts and institutional investors. The primary purpose is to disclose the company's earnings results for the first half of 2004 and announce a key executive appointment.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached exhibits (Exhibit 99.2 and Exhibit 99.3) but are not detailed in the cover document itself.
Material Changes and Corporate Actions
- Executive Appointment: On August 30, 2004, the company announced the appointment of Olivier Jacquesson as the new Head of Business Development.
- Earnings Announcement: On August 31, 2004, the company released its earnings results for the first half of 2004.
Guidance, Outlook, and Risks
The filing text does not provide specific details regarding future guidance, management commentary, risks, contingencies, or unusual items. Such information is presumed to be located in the incorporated presentation (Exhibit 99.3) and press release (Exhibit 99.2), which are not included in the provided text.
Investor Verification Checklist
- Review Exhibit 99.2 for specific First Half 2004 revenue, net income, and earnings per share figures.
- Examine Exhibit 99.3 for management's outlook, full-year guidance, and discussion of market risks.
- Verify the strategic impact of Olivier Jacquesson's appointment to Business Development as detailed in Exhibit 99.1.
- Confirm the incorporation of these documents into the Registration Statement on Form F-4 (No. 333-112314).